ATTORNEY GENERAL TONG LEADS BIPARTISAN COALITION URGING CONGRESS TO PASS LEGISLATION TO PROTECT COMMUNITIES FROM ILLICIT XYLAZINE
Yu, Janice
FOR IMMEDIATE RELEASE
Wednesday, April 1, 2026
Attorney General Tong Leads Bipartisan Coalition Urging Congress to Pass Legislation to Protect Communities from Illicit Xylazine
(Hartford, CT)- Attorney General William Tong is co-leading a bipartisan coalition of 40 other attorneys general in calling on Congress to pass the Combating Illicit Xylazine Act. The bipartisan legislation would classify the dangerous animal tranquilizer xylazine – which is often mixed with fentanyl and other opioids – as a federal controlled substance to better protect communities and reduce opioid overdose deaths. In a letter to House and Senate leadership, Attorney General Tong and the coalition explain the dangers of illicit xylazine, which is causing an increasing number of opioid overdose deaths, and argue that federally classifying xylazine as a controlled substance is essential to helping law enforcement stop the spread of the drug.
“Illicit xylazine is costing lives in Connecticut and across the country. It’s being mixed with opioids, driving deadly overdoses, and making this crisis even harder to fight. Congress must act now to make xylazine a controlled substance and give law enforcement the tools to stop its spread and save lives,” said Attorney General Tong.
Xylazine, widely known by its street name “tranq,” is a non-opioid veterinary tranquilizer used for large animals, including horses and deer, and is not approved for any human use. Xylazine is not an opioid and therefore does not respond to the overdose reversal drug naloxone, greatly increasing its lethality when mixed with opioids. In recent years, xylazine has been mixed with illicit opioids, most commonly fentanyl.
Attorney General Tong and the coalition argue that the lack of information on xylazine’s development, distribution, and related deaths makes it difficult to track and stop the spread of the drug. The Combating Illicit Xylazine Act would classify xylazine as a controlled substance, would allow the Drug Enforcement Administration (DEA) to track the manufacturing of the drug, prevent diversion, and mandate public reporting. With more information on the development, distribution, and use of xylazine, law enforcement professionals would be better equipped to fight against this rising threat. Last week, the Senate Judiciary Committee advanced the legislation with strong bipartisan support. In their letter, the attorneys general urge Congress to immediately pass this legislation to help address the opioid epidemic and save lives.
The letter is co-led by the attorneys general of Connecticut, New York, Arkansas, and Tennessee. Joining the letter are the attorneys general of Arizona, California, Colorado, Delaware, Georgia, Hawaii, Illinois, Indiana, Kansas, Louisiana, Michigan, Minnesota, Nevada, New Hampshire, New Mexico, North Carolina, North Dakota, Ohio, Oregon, Pennsylvania, Rhode Island, South Dakota, Utah, Vermont, Washington, West Virginia, American Samoa, the District of Columbia, and the U.S. Virgin Islands.
###
Elizabeth Benton
860-214-0937 (cell)
Janice Yu
Digital Director/Deputy Director of Communications
Office of the Attorney General
Hartford, CT 06106
Cell: +1 860-604-8967 |URL:
https://ct.gov/ag/
Confidential Information: The information contained in this e-mail is confidential and protected from general disclosure. If the recipient or the reader of this e-mail is not the intended recipient, or person responsible to receive this e-mail, you are requested to delete this e-mail immediately and do not disseminate or distribute or copy. If you have received this e-mail by mistake, please notify us immediately by replying to the message so that we can take appropriate action immediately and see to it that this mistake is rectified.
To unsubscribe, send an email from the account that received this message to list...@list.ct.gov with a blank subject and "unsubscribe AG-PressRelease" as the message body.